⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048976 | 0.94 | — | — | |
| SCHEMBL17048905 | 0.91 | — | — | |
| SCHEMBL15546447 | 0.81 | — | — | |
| SCHEMBL17049034 | 0.73 | — | — | |
| SCHEMBL910591 | 0.67 | — | — | |
| SCHEMBL15545776 | 0.67 | — | — | |
| SCHEMBL17048795 | 0.65 | — | — | |
| SCHEMBL17048979 | 0.65 | — | — | |
| SCHEMBL13194890 | 0.63 | — | — | |
| SCHEMBL31438418 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-04-16 | — | — | US | claimed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | claimed |
| EP-4298099-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022255408-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | WO | claimed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | claimed |
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-4298099-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022255408-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | WO | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20190047966-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2018229079-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | WO | disclosed |
| EP-3409662-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |